Borosil Ltd (BOROLTD) Q3FY25 Concall Summary - Dec-2024 Qtr
Performance Overview
- Borosil Ltd. sustained growth momentum in Q3 FY25, driven by execution across key categories, leading to industry-leading revenue growth for both the quarter and the nine-month period.
- Revenue from operations reached INR 837.6 crores in 9M FY25, a 17.1% YoY growth.
- Operating EBITDA (before investment and one-time income) reached INR 140.2 crores in 9M FY25, a 17.4% YoY growth, with a margin of 17%.
- The company faced headwinds due to the Uniform Code for Pharmaceutical Marketing Practices 2024, impacting B2B sales and necessitating a shift to online channels with higher marketing costs.
- Successful fundraising of INR 150 crores through a QIP in the quarter ended June 30, 2024, facilitated the repayment of loans.
Financial Metrics
Log in to Stocksigma to read the Financial Metrics section of this summary.
Operating Performance / Business Segments
Log in to Stocksigma to read the Operating Performance / Business Segments section of this summary.
Key Discussions & Insights
Log in to Stocksigma to read the Key Discussions & Insights section of this summary.
Outlook and Guidance
Log in to Stocksigma to read the Outlook and Guidance section of this summary.
Challenges / Concerns
Log in to Stocksigma to read the Challenges / Concerns section of this summary.
Industry / Competitive Landscape
Log in to Stocksigma to read the Industry / Competitive Landscape section of this summary.
Overall Summary
Log in to Stocksigma to read the Overall Summary section of this summary.